MetaCap

Merck (MRK) vs Vertex Pharmaceuticals (VRTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Merck (MRK) has outperformed Vertex Pharmaceuticals (VRTX) over the past year, gaining 36.8% versus a gain of 20.7%. Over five years, VRTX leads with a +180.5% price change compared with +68.9% for MRK. Merck is the larger company by market cap ($329.65 billion vs $130.58 billion), about 2.5 times the size, while Vertex Pharmaceuticals is growing revenue faster (+8.9% vs +1.3%).

On valuation, Merck trades at a lower forward P/E (14.9x vs 25.9x for Vertex Pharmaceuticals). Merck pays a dividend yielding 2.51%, while Vertex Pharmaceuticals does not currently pay one. Vertex Pharmaceuticals converts more of its revenue into profit, with a net margin of 32.9% versus 28.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MRK+36.78%VRTX+20.68%
+63%+30%-4%
Nov 21, 20251 yearNov 20, 2026
MRK+65.70%VRTX+181.62%
+216%+98%-21%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MRK versus VRTX key metrics
MetricMRKVRTX
Share price$133.72$515.02
Market cap$329.65B$130.58B
1-day change+0.69%-1.08%
YTD return+27.04%+13.60%
1-year return+36.78%+20.68%
5-year return+68.92%+180.53%
P/E ratio (TTM)135.0733.14
Forward P/E14.9225.86
EPS (TTM)$0.99$15.54
Dividend yield2.51%0.00%
Annual dividend$3.36$0.00
Revenue (latest FY)$65.01B$12.00B
Revenue growth (YoY)+1.31%+8.90%
Net income (latest FY)$18.25B$3.95B
Gross margin74.80%86.24%
Operating margin—34.77%
Net margin28.08%32.94%
52-week high$156.92$568.67
52-week low$96.06$412.27
Distance from 52-week high-14.78%-9.43%
Analyst consensusbuybuy
Avg. price target upside+20.80%+15.60%
Average volume9.81M1.25M
Shares outstanding2.47B253.54M
Employees73,0006,400
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Merck is about 2.5 times larger than Vertex Pharmaceuticals by market value ($329.65B vs $130.58B).
  • MRK has outperformed VRTX by 16.1 percentage points over the past year.
  • Merck trades at a higher earnings multiple (135.1x vs 33.1x trailing P/E).
  • Merck offers a meaningfully higher dividend yield (2.51% vs 0.00%).
  • Vertex Pharmaceuticals grew revenue faster in its latest fiscal year (+8.90% vs +1.31%).

About Merck

MRK stock →

Merck & Co., Inc. operates as a healthcare company worldwide.

Health Care · Biotechnology: Pharmaceutical Preparations · 73,000 employees

About Vertex Pharmaceuticals

VRTX stock →

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 6,400 employees

MRK vs VRTX FAQ

Which is bigger, Merck or Vertex Pharmaceuticals?

Merck (MRK) is larger, with a market capitalization of $329.65B compared with $130.58B for Vertex Pharmaceuticals (VRTX).

Which stock has performed better over the past year, MRK or VRTX?

MRK returned +36.78% over the past 12 months, compared with +20.68% for VRTX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, MRK or VRTX?

VRTX has the lower trailing P/E at 33.1, versus 135.1 for MRK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Merck or Vertex Pharmaceuticals?

Merck pays a dividend yielding 2.51%, while Vertex Pharmaceuticals does not currently pay a regular dividend.

Are Merck and Vertex Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons